SciSparc shares surge 48.28% premarket after acquiring MUSE GERD device patents and expected compliance with Nasdaq equity requirements.

SciSparc Ltd. (Nasdaq: SPRC) surged 48.28% in premarket trading following the announcement of a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property for the MUSE™ single-use endoscopic system from Xylo Technologies Ltd. The transaction, set to close on March 8, 2026, involves issuing shares representing 19.99% of SciSparc’s outstanding capital to Xylo. The MUSE™ system targets the $2.5 billion global GERD device market, with SciSparc planning to commercialize the technology post-closing and replicate Xylo’s successful licensing model in Greater China. While the company also disclosed Nasdaq non-compliance with minimum stockholders’ equity requirements, it outlined a plan to regain compliance by December 31, 2025, leveraging recent funding from debenture conversions and a registered direct offering. The premarket rally appears driven by optimism over the strategic expansion into the high-growth GERD market, overshadowing the listing compliance concerns.